Adults aged ≥18 years are recommended to receive COVID-19 vaccine
Adults aged ≥18 years without severe immunocompromise who have not previously received a COVID-19 vaccine are recommended a single primary dose.
All adults aged ≥75 years are recommended further doses of COVID-19 vaccine every 6 months.
Adults aged 65–74 years without severe immunocompromise are recommended further doses of COVID-19 vaccine every 12 months and can consider further doses every 6 months based on a risk–benefit assessment.
Adults aged 18–64 years without severe immunocompromise can consider further doses every 12 months based on a risk–benefit assessment, such as the presence of other medical conditions that may increase the risk of severe COVID-19.
This list is based on emerging evidence and expert opinion. Children and adults with these risk conditions may be at increased risk of severe COVID-19. These examples are not exhaustive, and providers may include individuals with conditions similar to those listed below based on clinical judgement.
| Condition | Example medical condition |
|---|---|
| Immunocompromising condition | Immunocompromise due to disease or treatment, asplenia or splenic dysfunction, HIV infection, malignancy, solid organ transplant, haematopoietic stem cell transplant *Individuals with severe immunocompromise are recommended additional COVID-19 vaccines doses. See Table. Severely immunocompromising conditions for which additional doses of COVID-19 vaccine are recommended. |
| Cardiac disease | Congenital heart disease, congestive heart failure, coronary artery disease |
| Chronic respiratory condition | Severe asthma, cystic fibrosis, bronchiectasis, suppurative lung disease, chronic obstructive pulmonary disease, chronic emphysema |
| Chronic neurological condition | Hereditary and degenerative CNS disease, seizure disorder, spinal cord injury, neuromuscular disorder, condition which increases respiratory infection risk |
| Chronic metabolic condition | Type 1 or 2 diabetes, amino acid disorder, carbohydrate disorder, cholesterol biosynthesis disorder, fatty acid oxidation defect, lactic acidosis, mitochondrial disorder, organic acid disorder, urea cycle disorder, vitamin/cofactor disorder, porphyria |
| Chronic kidney disease Stage 4 and 5 | |
| Haematological disorder | Haemoglobinopathy |
| Chronic liver disease | Cirrhosis, autoimmune hepatitis, non-alcoholic fatty liver disease, alcoholic liver disease |
| Chromosomal abnormality | Trisomy 21 |
| Obesity, body mass index ≥30 kg per m2 |
A person may be vaccinated earlier than the recommended interval in exceptional circumstances, such as before starting immunosuppressant therapy, before overseas travel or if someone cannot reschedule vaccination easily (such as in an outreach vaccination program).
Comirnaty JN.1 and Omicron XBB.1.5-based vaccines are the available vaccines for use. Adults may receive Comirnaty Omicron XBB.1.5 ≥12 years formulation (dark grey cap), and Comirnaty JN.1 ≥12 years formulation (dark grey cap).